Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| CD47 Targeting Therapeutics Market Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic | ||
| By: PR Newswire Association LLC. - 29 Jun 2022 | Back to overview list |
|
|
JERSEY CITY, N.J., June 29, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the 'Global CD47 Targeting Therapeutics Market By Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers, Other Diseases Indications), By Type of molecule(Biologics, Small molecule) - Market Outlook and Industry Analysis 2030.'  According to the latest research by InsightAce Analytic, the global CD47 targeting therapeutics market size is expected to record a promising CAGR of 67% during the period of 2022-2030. Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1290 One key mechanism of tumour cell immune escape is the overexpression of an immunoglobulin, CD47. CD47 is a transmembrane protein that glycosylates on the surface of different cancer cells and helps survive cancer cells in various cancer types. In many cancer types, the binding of CD47 to signal-regulatory protein ? (SIRP?) initiates an inhibitory signalling pathway that prevents malignant cells from phagocytosis by macrophages. Therefore, inhibition of the CD47-SIRP? signalling pathway can enhance the phagocytosis of tumour cells by macrophages. The growth of the global CD47 targeting therapeutics market can be attributed to several factors, such as the increase in adoption of CD47-targeting anti-cancer therapies, growing geriatric population, high prevalence of various cancer types, and rising awareness among people regarding the advantages of targeting therapeutics. Additionally, the increasing R&D investments to improve the understanding of CD47-dependent signalling are anticipated to create new opportunities for the CD47 targeting the therapeutics market over the forecast period. Improved knowledge in this field of research could lead to the innovation of advanced and effective anti-tumour therapies that act through the inhibition of CD47 signalling in cancer cells. For instance, in June 2021, Trillium Therapeutics Inc. (Canada), a company engaged in developing innovative therapies for cancer treatments, developed a checkpoint inhibitor of the innate immune system, TTI-621 (SIRP?-IgG1 Fc), in combination with doxorubicin. TTI-621 binds CD47, an innate immune checkpoint that binds SIRP? and delivers a "don't eat me" signal to suppress macrophage phagocytosis. However, the expensive production and complex manufacturing of target therapies, damage to normal cells while exerting an anti-tumour effect, and strict government regulations for therapy approvals are expected to limit the market adoption during the forecast years. By region, the North America region is expected to witness significant growth over the forecast period (2022-2030) due to the fast adoption of innovative drugs and therapy techniques and the increasing number of cancer patients and cancer mortalities in this region. Request for ToC/Proposal: https://www.insightaceanalytic.com/report/global-cd47-targeting-therapeutics-market-/1290 Major market players operating in the CD47 targeting therapeutics market include Abpro (US), ALX Oncology (US), Apmonia Therapeutics (France), Arch Oncology (US), Aurigene (Bangalore), Bristol Myers Squibb (US), Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US) TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, among others. Key developments in the market:
Market Segments Global CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Valu US$ Mn)
Global CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
Global CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)
North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Why should buy this report:
For More Information at https://www.insightaceanalytic.com/customisation/1290 Other Related Reports Published by InsightAce Analytic: Global Novel T-Cell Immunotherapies Market Global Allogeneic Cell Therapy Manufacturing Market Global Regulatory T-Cell (Tregs) Therapies Market Global CAR T-Cell Therapy For Multiple Myeloma Market Global Immuno-Oncology Cell Therapy Market About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg 
|
||
|
|
||
 | Back to overview list | |